Disc Medicine, Inc. (IRON) intrinsic value & 10-year financials
Disc Medicine, Inc. (IRON) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $56.84
- Market cap
- $2.0B
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- -17.1%
- Free cash flow (FY2025)
- -$181.3M
IRON 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$212.2M | -$6.01 | -$181.3M | — | -49.2% |
| FY2024 | — | -$109.4M | -$3.96 | -$94.4M | — | -97.1% |
| FY2023 | — | -$76.4M | -$3.42 | -$73.6M | — | 591.5% |
| FY2022 | — | -$46.8M | -$2.15 | -$42.4M | — | 346.1% |
| FY2021 | — | -$71.9M | -$1.95 | -$59.8M | — | -755.5% |
| FY2020 | — | -$40.8M | — | -$32.7M | — | -138.5% |
| FY2019 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Disc Medicine, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Disc Medicine, Inc. has historically struggled to out-earn its cost of capital, averaging just -47.2% ROIC.
Disc Medicine, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Disc Medicine, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.